New H1N1 VLP Flu Vaccine trial in Mexico

This post was written by admin on October 20, 2009
Posted Under: Health, Investing, Technology, US

Novavax, Inc. announced today that it has initiated a two-stage clinical study of its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare. Avimex distributes biological and pharmaceutical products for use in Mexico and more than 25 other countries around the world. Avimex is providing financial support for the trial and is expected to distribute the H1N1 VLP vaccine in Mexico in 2010 if it is approved for commercial sale. In addition, Novavax also announced today that GE Healthcare (a unit of General Electric Company (NYSE: GE – News)) has agreed to support this program by providing its single-use bioprocessing technologies for vaccine production. GE Healthcare and Novavax have worked together since December 2007 to develop innovative vaccine production solutions using GE Healthcare’s manufacturing technologies.

The video can be viewed at Novavax Starts H1N1 Vaccine Study

Add a Comment

required, use real name
required, will not be published
optional, your blog address

Next Post:
Previose Post: